Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Paolo Tarantino, Ilaria Attili, Filippo de Marinis, Giuseppe Curigliano, Valeria Stati, Antonio Passaro
Publikováno v:
Lung Cancer. 154:151-160
The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), but most patients develop resistance to ICI treatment over time. Resistance to ICIs is mediate
Autor:
Jillian Wilhelmina Paulina Bracht, Valentina Guarneri, Ana Giménez-Capitán, Carles Codony-Servat, Filippo de Marinis, Giulia Pasello, Miguel Angel Molina-Vila, Rafael Rosell, Pierfranco Conte, Antonio Passaro, Imane Chaib, Matteo Fassan, Alessandro Dal Maso, Jordi Codony-Servat, Erika Aldeguer, Niki Karachaliou, Laura Bonanno, Jordi Berenguer, Ilaria Attili
Publikováno v:
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
Background: The role of MET alterations in non-small cell lung cancer (NSCLC) is increasing and several targeted agents are under evaluation. MET exon 14 skipping mutations and MET amplifications are associated with potential sensitivity to MET inhib
Autor:
Lorenzo Spaggiari, Marina Chiara Garassino, Filippo de Marinis, Roberto Ferrara, Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Gaia Piperno, Giuseppe Lo Russo, Giulia Corrao, Roberto Orecchia, Simone Giovanni Gugliandolo
Publikováno v:
Lung Cancer. 142:70-79
Presence of liver metastases correlates with worse survival and response to any treatments. This may be due to the microenvironment of liver which leads tumor to escape from Immune System. Stereotactic Body Radiation Therapy may help to sensitize Imm
Autor:
Filippo de Marinis, Helano C. Freitas, Yi-Long Wu, David Vicente, Gee-Chen Chang, Mariano Provencio, Nicolaas A. Bakker, J. Rigas, Sang We Kim, Qing Zhou, Liyan Jiang, Parneet Cheema, Gilberto de Castro, Claudio Martin, Giulio Metro, Byoung Chul Cho, Miguel F. Miranda, Johan Vansteenkiste, Yuh Min Chen
Publikováno v:
Future Oncology. 15:3003-3014
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive advanced non-small-cell lung cancer adults, who received ≥1 prior
Autor:
Jun Zhao, B J Srinivasa, Hai-Yan Tu, Konstantin Laktionov, Filippo de Marinis, Tejaswini Jalikop, Jifeng Feng, Eng Huat Tan, Victor C. S. Lee, Cheng-Ta Yang, Dariusz M. Kowalski, Maya Gottfried, Yi-Long Wu, Artem Poltoratskiy, Dennis Chin-Lun Huang, Agnieszka Cseh, Keunchil Park, L. Clementi, Antonio Passaro
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundAfatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of
Autor:
Ilaria Attili, Filippo de Marinis, Emilio Bria, Domenico Galetta, Alain Gelibter, Maria Lucia Reale, Diana Giannarelli, Valeria Stati, Pamela Pizzutilo, Alessio Stefani, Silvia Novello, Antonio Passaro, Simona Carnio, Emanuele Vita
Publikováno v:
Cancers, Vol 13, Iss 2935, p 2935 (2021)
Cancers
Volume 13
Issue 12
Cancers
Volume 13
Issue 12
Background: Pembrolizumab is approved in monotherapy for the first-line (1L) of advanced or metastatic NSCLC patients with high PD-L1 (≥50%). Despite a proportion of patients achieve long-term survival, about one-third of patients experience detrim
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Ester Del Signore, Francesco Petrella, Filippo de Marinis, Patrick Maisonneuve, Monica Casiraghi, Lorenzo Spaggiari, Giulia Sedda, Gaia Piperno
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objective Since data from large retrospective observational studies and cancer registries became available, suggesting a benefit for patients undergoing surgery, the role of surgery in the treatment of small cell lung cancer (SCLC) needs to be recons
Autor:
Gianluca Spitaleri, Ilaria Attili, Stefania Morganti, Letizia Gianoncelli, Valeria Stati, Davide Radice, Ester Del Signore, Chiara Catania, Filippo de Marinis
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
In February 2020, Italy became one of the first countries to be plagued by the SARS-CoV-2 pandemic, COVID-19. In March 2020, the Italian government decreed a lockdown for the whole country, which overturned communication systems, hospital organizatio
Autor:
Maximilian Hochmair, A. Poltoratskiy, Michael Schumacher, Rafal Dziadziuszko, Silvia Novello, Konstantin Laktionov, Inna Egorova, Maria Rita Migliorino, Filippo de Marinis, W. Tang, Daphne Tsoi, Simona Rizzato, Gyula Ostoros, Antonio Passaro, L. Clementi, Agnieszka Cseh, Guzel Z Mukhametshina, Giulio Metro, Dariusz M. Kowalski, Maya Gottfried
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable treatment option for patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small cell lung cancer (NSCLC). However, such studies often excl